She S

References (3)

Title : Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study - Ren_2025_Front.Immunol_16_1692632
Author(s) : Ren L , Chen D , Zhang X , She S , Fei R , Cong X , Mu S , Zhou Y , Gao J , Liao W , Chen H
Ref : Front Immunol , 16 :1692632 , 2025
Abstract :
PubMedSearch : Ren_2025_Front.Immunol_16_1692632
PubMedID: 41376633

Title : Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study - Ren_2025_Front.Immunol_16_1692632
Author(s) : Ren L , Chen D , Zhang X , She S , Fei R , Cong X , Mu S , Zhou Y , Gao J , Liao W , Chen H
Ref : Front Immunol , 16 :1692632 , 2025
Abstract :
PubMedSearch : Ren_2025_Front.Immunol_16_1692632
PubMedID: 41376633

Title : Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study - Ren_2025_Front.Immunol_16_1692632
Author(s) : Ren L , Chen D , Zhang X , She S , Fei R , Cong X , Mu S , Zhou Y , Gao J , Liao W , Chen H
Ref : Front Immunol , 16 :1692632 , 2025
Abstract :
PubMedSearch : Ren_2025_Front.Immunol_16_1692632
PubMedID: 41376633